32 Warnaar N, Hofker HS, Maathuis MHJ, Niesing J, Bruggink AH, Dijkstra G, et al. Matrix metalloproteinases as profibrotic factors in terminal ileum in Crohn’s disease. Inflamm Bowel Dis 2006;12(9):863-9. doi: 10.1097/01.mib.0000231568.43065.ed. Gecse K, Khanna R, Stoker J, Jenkins JT, Gabe S, Hahnloser D, et al. Fistulizing Crohn’s disease: Diagnosis and management. United European Gastroenterol J 2013;1(3):206-13. doi: 10.1177/2050640613487194. Kirkegaard T, Hansen A, Bruun E, Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease. Gut 2004;53(5):701-9. doi: 10.1136/ gut.2003.017442. Panés J, Bouzar R, Chaparro M, García-Sánchez V, Gisbert JP, Martínez de Guereñu B, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther 2011;34(2):125-45. doi: 10.1111/j.1365-2036.2011.04710.x. Booya F, Akram S, Fletcher JG, Huprich JE, Johnson CD, Fidler JL, et al. CT enterography and fistulizing Crohn’s disease: clinical benefit and radiographic findings. Abdom Imaging 2009;34(4):467-75. doi: 10.1007/s00261-008-9419-1. Buchanan GN, Halligan S, Bartram CI, Williams AB, Tarroni D, Cohen CRG. Clinical examination, endosonography, and MR imaging in preoperative assessment of fistula in ano: comparison with outcome-based reference standard. Radiology 2004;233(3):674-81. doi: 10.1148/radiol.2333031724. Rieder F, Fiocchi C, Rogler G. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology 2017;152(2):340-350.e6. doi: 10.1053/j. gastro.2016.09.047. Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol 2015;110(1):114-26. doi: 10.1038/ajg.2014.357. Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017;376(18):1723-1736. doi: 10.1056/ NEJMoa1606910. Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D’Haens G, et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s disease. Gastroenterology 2020;158(8):2123-2138.e8. doi: 10.1053/j.gastro.2020.01.047. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther 2016;43(1):30-51. doi: 10.1111/apt.13445. Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol 2018;53(9):1048-1064. doi: 10.1007/s00535-018-1480-0. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Barre A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther 2018;47(7):896-905. doi: 10.1111/apt.14550. Bernstein CN, Ng SC, Lakatos PL, Moum B, Loftus EV Jr; Epidemiology and Natural History Task Force of the International Organization of the Study of Inflammatory Bowel Disease. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013;19(9):2001-10. doi: 10.1097/MIB.0b013e318281f3bb. 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Chapter 1
RkJQdWJsaXNoZXIy MjY0ODMw